{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:54:38Z","timestamp":1793915678141,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013318","name":"Shanxi Science and Technology Department","doi-asserted-by":"crossref","award":["20210302123245"],"award-info":[{"award-number":["20210302123245"]}],"id":[{"id":"10.13039\/501100013318","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Founding of Health Commission of Shanxi Province","award":["2019034"],"award-info":[{"award-number":["2019034"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79918-7","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T03:21:35Z","timestamp":1731900095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis"],"prefix":"10.1038","volume":"14","author":[{"given":"Jing","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingna","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weisong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"79918_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(15)00145-3","author":"G Nils Erik","year":"2015","unstructured":"Nils Erik, G. & Jan, V. J. Myasthenia gravis: Subgroup classification and therapeutic strategies. Lancet Neurol. https:\/\/doi.org\/10.1016\/s1474-4422(15)00145-3 (2015).","journal-title":"Lancet Neurol."},{"key":"79918_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102800","author":"Z Rui","year":"2021","unstructured":"Rui, Z., Sushan, L. & Chongbo, Z. The role of innate immunity in myasthenia gravis. Autoimmun. Rev. https:\/\/doi.org\/10.1016\/j.autrev.2021.102800 (2021).","journal-title":"Autoimmun. Rev."},{"key":"79918_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.593431","author":"W Ying","year":"2021","unstructured":"Ying, W., Jie, L. & Oliver, G. A. Immunoregulatory cells in myasthenia gravis. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.593431 (2021).","journal-title":"Front Neurol."},{"key":"79918_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22312","author":"H Osamu","year":"2011","unstructured":"Osamu, H. et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. https:\/\/doi.org\/10.1002\/ana.22312 (2011).","journal-title":"Ann. Neurol."},{"key":"79918_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125","author":"FH James Jr","year":"2020","unstructured":"James, F. H. Jr. et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: Results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2019.5125 (2020).","journal-title":"JAMA Neurol."},{"key":"79918_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00212","author":"L Konstantinos","year":"2020","unstructured":"Konstantinos, L. & Socrates, T. J. Autoantibody specificities in myasthenia gravis; Implications for improved diagnostics and therapeutics. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.00212 (2020).","journal-title":"Front. Immunol."},{"key":"79918_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000002790","author":"BS Donald","year":"2016","unstructured":"Donald, B. S. et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology https:\/\/doi.org\/10.1212\/wnl.0000000000002790 (2016).","journal-title":"Neurology"},{"key":"79918_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000008688","author":"N Bernhard","year":"2019","unstructured":"Bernhard, N. et al. Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases. Neurology https:\/\/doi.org\/10.1212\/wnl.0000000000008688 (2019).","journal-title":"Neurology"},{"key":"79918_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.48.5.1253","author":"CE Thomas","year":"1997","unstructured":"Thomas, C. E. et al. Myasthenic crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology https:\/\/doi.org\/10.1212\/wnl.48.5.1253 (1997).","journal-title":"Neurology"},{"key":"79918_CR10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015370","author":"C Mischa Li","year":"2022","unstructured":"Mischa Li, C., Chesinta, V. & Sean, S. R. Shortage of plasma-derived products: A looming crisis?. Blood https:\/\/doi.org\/10.1182\/blood.2021015370 (2022).","journal-title":"Blood"},{"key":"79918_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-4598(199911)22:11<1479::aid-mus3>3.0.co;2-b","author":"MC Dalakas","year":"1999","unstructured":"Dalakas, M. C. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle Nerve https:\/\/doi.org\/10.1002\/(sici)1097-4598(199911)22:11%3c1479::aid-mus3%3e3.0.co;2-b (1999).","journal-title":"Muscle Nerve"},{"key":"79918_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-003-0082-6","author":"MM Eibl","year":"2003","unstructured":"Eibl, M. M. Intravenous immunoglobulins in neurological disorders: Safety issues. Neurol. Sci. https:\/\/doi.org\/10.1007\/s10072-003-0082-6 (2003).","journal-title":"Neurol. Sci."},{"key":"79918_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/jci97911","author":"U Peter","year":"2018","unstructured":"Peter, U. et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J. Clin. Invest. https:\/\/doi.org\/10.1172\/jci97911 (2018).","journal-title":"J. Clin. Invest."},{"key":"79918_CR14","doi-asserted-by":"publisher","DOI":"10.5603\/ait.2013.0002","author":"S Wojciech","year":"2013","unstructured":"Wojciech, S. et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol. Intensive Ther. https:\/\/doi.org\/10.5603\/ait.2013.0002 (2013).","journal-title":"Anaesthesiol. Intensive Ther."},{"issue":"3","key":"79918_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"N Pushpa","year":"2021","unstructured":"Pushpa, N. et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 96(3), 114\u2013122 (2021).","journal-title":"Neurology."},{"issue":"2","key":"79918_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1212\/wnl.45.2.338","volume":"45","author":"D Grob","year":"1995","unstructured":"Grob, D. et al. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 45(2), 338\u2013344. https:\/\/doi.org\/10.1212\/wnl.45.2.338 (1995).","journal-title":"Neurology"},{"issue":"3","key":"79918_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","volume":"146","author":"H Peter","year":"2020","unstructured":"Peter, H. et al. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. J. Allergy Clin. Immunol. 146(3), 479-491.e5. https:\/\/doi.org\/10.1016\/j.jaci.2020.07.016 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"79918_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20317","author":"K Wolfgang","year":"2011","unstructured":"Wolfgang, K., Christoph, B. & Reinhard, K. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J. Clin. Apher https:\/\/doi.org\/10.1002\/jca.20317 (2011).","journal-title":"J. Clin. Apher"},{"issue":"4","key":"79918_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.anai.2014.06.025","volume":"113","author":"M Celiksoy","year":"2014","unstructured":"Celiksoy, M. et al. Relationship between hypogammaglobulinemia and severity of atopic dermatitis. Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol. 113(4), 467\u2013469. https:\/\/doi.org\/10.1016\/j.anai.2014.06.025 (2014).","journal-title":"Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol."},{"issue":"5","key":"79918_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/PCC.0b013e318241793d","volume":"13","author":"A Hoskote","year":"2012","unstructured":"Hoskote, A. et al. Role of immunoglobulin supplementation for secondary immunodeficiency associated with chylothorax after pediatric cardiothoracic surgery. Pediatr. Crit. Care Med. A J. Soc. Crit. Care Med. World Fed. Pediatr. Intensive Crit. Care Soc. 13(5), 535\u2013541. https:\/\/doi.org\/10.1097\/PCC.0b013e318241793d (2012).","journal-title":"Pediatr. Crit. Care Med. A J. Soc. Crit. Care Med. World Fed. Pediatr. Intensive Crit. Care Soc."},{"issue":"3","key":"79918_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan, A. et al. Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J. Clin. Apheresis 34(3), 171\u2013354. https:\/\/doi.org\/10.1002\/jca.21705 (2019).","journal-title":"J. Clin. Apheresis"},{"key":"79918_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/nri2155","author":"CR Derry","year":"2007","unstructured":"Derry, C. R. & Shreeram, A. FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/nri2155 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"79918_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-01000-z","author":"H Young-A","year":"2023","unstructured":"Young-A, H. Efgartigimod alfa in generalised myasthenia gravis: A profile of its use. CNS Drugs https:\/\/doi.org\/10.1007\/s40263-023-01000-z (2023).","journal-title":"CNS Drugs"},{"key":"79918_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9","author":"FH James Jr","year":"2021","unstructured":"James, F. H. Jr. et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9 (2021).","journal-title":"Lancet Neurol."},{"key":"79918_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1321058","author":"W Keiko","year":"2024","unstructured":"Keiko, W. et al. Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2024.1321058 (2024).","journal-title":"Front Neurol."},{"key":"79918_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28178","author":"S Fang","year":"2024","unstructured":"Fang, S. et al. Efgartigimod infusion in the treatment regimen for myasthenic crisis: A case report. Muscle Nerve https:\/\/doi.org\/10.1002\/mus.28178 (2024).","journal-title":"Muscle Nerve"},{"key":"79918_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/9455237","author":"AO Omar","year":"2024","unstructured":"Omar, A. O. et al. Efgartigimod as rescue medication in a patient with therapy-refractory myasthenic crisis. Case Rep. Neurol. Med. https:\/\/doi.org\/10.1155\/2024\/9455237 (2024).","journal-title":"Case Rep. Neurol. Med."},{"key":"79918_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241254895","author":"Z Zhouao","year":"2024","unstructured":"Zhouao, Z. et al. Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: A case report. Ther. Adv. Neurol. Disord. https:\/\/doi.org\/10.1177\/17562864241254895 (2024).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"79918_CR29","doi-asserted-by":"publisher","unstructured":"A 3rd, J., et al., Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology, 2000. 55(1). https:\/\/doi.org\/10.1212\/wnl.55.1.16","DOI":"10.1212\/wnl.55.1.16"},{"key":"79918_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.7.1487","author":"GI Wolfe","year":"1999","unstructured":"Wolfe, G. I. et al. Myasthenia gravis activities of daily living profile. Neurology https:\/\/doi.org\/10.1212\/wnl.52.7.1487 (1999).","journal-title":"Neurology"},{"key":"79918_CR31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1b1e","author":"TM Burns","year":"2010","unstructured":"Burns, T. M., Mark, C. & Donald, S. B. The MG composite: A valid and reliable outcome measure for myasthenia gravis. Neurology https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1b1e (2010).","journal-title":"Neurology"},{"key":"79918_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","author":"RJ Barohn","year":"1998","unstructured":"Barohn, R. J. et al. Reliability testing of the quantitative myasthenia gravis score. Ann. N. Y. Acad. Sci. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb11015.x (1998).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"79918_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25198","author":"MB Ted","year":"2016","unstructured":"Ted, M. B. et al. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve https:\/\/doi.org\/10.1002\/mus.25198 (2016).","journal-title":"Muscle Nerve"},{"issue":"6","key":"79918_CR34","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi, S. et al. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 65(6), 630\u2013639. https:\/\/doi.org\/10.1002\/mus.27476 (2022).","journal-title":"Muscle Nerve"},{"issue":"1","key":"79918_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke, C. et al. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J. Neuroinflamm. 19(1), 89. https:\/\/doi.org\/10.1186\/s12974-022-02448-4 (2022).","journal-title":"J. Neuroinflamm."},{"issue":"23","key":"79918_CR36","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1212\/wnl.0000000000004676","volume":"89","author":"C Barnett","year":"2017","unstructured":"Barnett, C. et al. Myasthenia gravis impairment index: Responsiveness, meaningful change, and relative efficiency. Neurology 89(23), 2357\u20132364. https:\/\/doi.org\/10.1212\/wnl.0000000000004676 (2017).","journal-title":"Neurology"},{"key":"79918_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9524-2","author":"F Saskia","year":"2017","unstructured":"Saskia, F., Charlotte, K. & Wilhelm, H. Impact of altered endogenous IgG on unspecific mAb clearance. J. Pharmacokinet. Pharmacodyn. https:\/\/doi.org\/10.1007\/s10928-017-9524-2 (2017).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"79918_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1143","author":"V Carlos","year":"2005","unstructured":"Carlos, V. et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/nbt1143 (2005).","journal-title":"Nat. Biotechnol."},{"key":"79918_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830260327","author":"V Ghetie","year":"1996","unstructured":"Ghetie, V. et al. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur. J. Immunol. https:\/\/doi.org\/10.1002\/eji.1830260327 (1996).","journal-title":"Eur. J. Immunol."},{"key":"79918_CR40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.9.5171","author":"WFD Acqua","year":"2002","unstructured":"Acqua, W. F. D. et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: Biological consequences. J. Immunol. https:\/\/doi.org\/10.4049\/jimmunol.169.9.5171 (2002).","journal-title":"J. Immunol."},{"key":"79918_CR41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.603712","author":"MB Jack","year":"2014","unstructured":"Jack, M. B. et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J. Biol. Chem. https:\/\/doi.org\/10.1074\/jbc.M114.603712 (2014).","journal-title":"J. Biol. Chem."},{"key":"79918_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12016-2","author":"N Bernhard","year":"2023","unstructured":"Bernhard, N. et al. Weaning and extubation failure in myasthenic crisis: A multicenter analysis. J. Neurol. https:\/\/doi.org\/10.1007\/s00415-023-12016-2 (2023).","journal-title":"J. Neurol."},{"key":"79918_CR43","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.3.629","author":"AI Qureshi","year":"1999","unstructured":"Qureshi, A. I. et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology https:\/\/doi.org\/10.1212\/wnl.52.3.629 (1999).","journal-title":"Neurology"},{"key":"79918_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615","author":"P Gajdos","year":"1997","unstructured":"Gajdos, P. et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol. https:\/\/doi.org\/10.1002\/ana.410410615 (1997).","journal-title":"Ann. Neurol."},{"key":"79918_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.5.578","author":"N Shibuya","year":"1994","unstructured":"Shibuya, N. et al. Immunoadsorption therapy for myasthenia gravis. J. Neurol. Neurosurg. Psychiatry https:\/\/doi.org\/10.1136\/jnnp.57.5.578 (1994).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"79918_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22139","author":"M Aditya","year":"2010","unstructured":"Aditya, M. et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann. Neurol. https:\/\/doi.org\/10.1002\/ana.22139 (2010).","journal-title":"Ann. Neurol."},{"key":"79918_CR47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e5505","author":"D Barth","year":"2011","unstructured":"Barth, D. et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology https:\/\/doi.org\/10.1212\/WNL.0b013e31821e5505 (2011).","journal-title":"Neurology"},{"issue":"3","key":"79918_CR48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1385\/criai:29:3:173","volume":"29","author":"H Orbach","year":"2005","unstructured":"Orbach, H. et al. Intravenous immunoglobulin: Adverse effects and safe administration. Clin. Rev. Allergy Immunol. 29(3), 173\u2013184. https:\/\/doi.org\/10.1385\/criai:29:3:173 (2005).","journal-title":"Clin. Rev. Allergy Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79918-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79918-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79918-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T02:07:15Z","timestamp":1732241235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79918-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79918"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79918-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors agreed with the content of the manuscript, and all patients or legal guardians consented to the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"28394"}}